Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have been given an average rating of “Buy” by the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $31.00.

Several analysts recently issued reports on the company. Leerink Partners assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target on the stock. Jefferies Financial Group began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 target price on the stock. Leerink Partnrs raised shares of Maplight Therapeutics to a “strong-buy” rating in a report on Friday, November 21st. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Finally, Morgan Stanley began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price for the company.

Maplight Therapeutics Stock Performance

Maplight Therapeutics stock opened at $18.02 on Friday. Maplight Therapeutics has a 1 year low of $12.24 and a 1 year high of $21.55. The business has a 50-day simple moving average of $16.70. The company has a market cap of $817.62 million and a P/E ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.